Ethnic Differences in Breast Cancer Treatments, Outcomes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 2
Volume 12
Issue 2

SEATTLE-A Fred Hutchinson Cancer Research Center study documents important disparities in breast cancer diagnosis, treatment, and survival among American women of various ethnicities. The findings by Christopher Li, MD, PhD, and his colleagues (Arch Intern Med 163:49-56, 2003) are based on data from 11 tumor registries participating in the Surveillance, Epidemiology, and End Results (SEER) program, including 124,934 women diagnosed with first primary invasive breast cancer from 1992 to 1998.

SEATTLE—A Fred Hutchinson Cancer Research Center study documents important disparities in breast cancer diagnosis, treatment, and survival among American women of various ethnicities. The findings by Christopher Li, MD, PhD, and his colleagues (Arch Intern Med 163:49-56, 2003) are based on data from 11 tumor registries participating in the Surveillance, Epidemiology, and End Results (SEER) program, including 124,934 women diagnosed with first primary invasive breast cancer from 1992 to 1998.

The analysis showed that blacks, American Indians, Hawaiians, Indians and Pakistanis, Mexicans, South and Central Americans, and Puerto Ricans had a 1.4- to 3.6-fold greater risk of presenting with stage IV breast cancer, relative to non-Hispanic whites. Blacks, Mexicans, and Puerto Ricans were 20% to 50% more likely to receive a first course of surgical and radiation therapy that did not meet the 2000 National Comprehensive Cancer Network (NCCN) guidelines. Blacks, American Indians, Hawaiians, Vietnamese, Mexicans, South and Central Americans, and Puerto Ricans had a 20% to 200% greater mortality risk after a breast cancer diagnosis. 

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content